{"organizations": [], "uuid": "2dd206874835c5d20fcf7daf52923b94f6b750c1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180510.html", "section_title": "Archive News &amp; Video for Thursday, 10 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ligand-pharmaceuticals-entered-com/brief-ligand-pharmaceuticals-entered-commercial-platform-license-agreement-with-ksq-therapeutics-idUSFWN1SH0Q4", "country": "US", "domain_rank": 408, "title": "BRIEF-Ligand Pharmaceuticals Entered Commercial Platform License Agreement, With KSQ Therapeutics", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.281, "site_type": "news", "published": "2018-05-10T18:49:00.000+03:00", "replies_count": 0, "uuid": "2dd206874835c5d20fcf7daf52923b94f6b750c1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ligand-pharmaceuticals-entered-com/brief-ligand-pharmaceuticals-entered-commercial-platform-license-agreement-with-ksq-therapeutics-idUSFWN1SH0Q4", "ord_in_thread": 0, "title": "BRIEF-Ligand Pharmaceuticals Entered Commercial Platform License Agreement, With KSQ Therapeutics", "locations": [], "entities": {"persons": [{"name": "commerci", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "ligand pharmaceuticals inc", "sentiment": "negative"}, {"name": "ksq therapeutics", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}, {"name": "ligand", "sentiment": "none"}, {"name": "inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 10 (Reuters) - Ligand Pharmaceuticals Inc:\n* LIGAND PHARMACEUTICALS - ON MAY 8, ENTERED COMMERCIAL PLATFORM LICENSE AGREEMENT, WITH KSQ THERAPEUTICS, INC - SEC FILING\n* LIGAND PHARMACEUTICALS INC - KSQ TO BE ABLE TO USE COâ€™S FULL OMNIAB PLATFORM TO DISCOVER ANTIBODIES\n* LIGAND - RECEIVED UPFRONT PAYMENT, ELIGIBLE TO RECEIVE ANNUAL PLATFORM ACCESS PAYMENTS, DEVELOPMENT & REGULATORY MILESTONE PAYMENTS AMONG OTHERS\n* LIGAND PHARMACEUTICALS INC - KSQ TO BE RESPONSIBLE FOR ALL COSTS RELATED TO ITS ANTIBODY DEVELOPMENT PROGRAM Source text: [ bit.ly/2rzArcO ] Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://bit.ly/2rzArcO", "https://instagram.com/reuters/"], "published": "2018-05-10T18:49:00.000+03:00", "crawled": "2018-05-11T12:53:04.001+03:00", "highlightTitle": ""}